sdf-1α-cxcr4

LY2510924 is an effective and selective CXCR4 antagonist. It blocks SDF-1 binding to CXCR4 (IC50: 0.079 nM).

FC131 TFA (606968-52-9 free base) (FC131 TFA) is an antagonist of CXCR4 that inhibits the binding of [125I] -sdf-1 to CXCR4(IC50 : 4.5 nM ), and has anti-hiv activity.

Alx40-4C trifluoroacetate is a chemokine receptor (CXCR4) inhibitor, which inhibits the binding of sdf-1 to CXCR4.Alx40-4ctrifluoroacetate was also an APJ receptor antagonist with an IC50 value of 2.9 M.

ALX40-4C is a small peptide inhibitor of the chemokine receptor CXCR4 that can inhibit X4 strains of HIV-1.

Me6TREN 4HCl is a potent and efficacious mobilizing agent of hematopoietic stem and progenitor cells (HSPCs) that can act by activating MMP-9 expression and disrupting the SDF-1α/CXCR4 axis, exhibiting more significant mobilizing effects than G-CSF or AMD

KRH-3955 hydrochloride is a CXCR4 antagonist with oral bioavailability. It effectively inhibits the binding of SDF-1α to CXCR4, exhibiting an IC 50 of 0.61 nM. Additionally, KRH-3955 hydrochloride displays high potency and selectivity as an inhibitor of X4 HIV-1, with an EC 50 ranging from 0.3 to 1.0 nM.

HF51116 is a potent antagonist of CXCR4 that significantly inhibits SDF-1α-induced cell migration, calcium mobilization, and CXCR4 internalization. It also prevents HIV-1 infection utilizing CXCR4. HF51116 has shown investigational potential for HIV-1 infection, hematopoietic stem cell mobilization, and cancer metastasis.

CTCE-0214, a chemokine CXC receptor 4 (CXCR4) agonist and SDF-1α (stromal cell-derived factor-1α) peptide analog, exhibits anti-inflammatory properties. It is applicable in the research of inflammation, sepsis, and systemic inflammatory syndromes [1] [2] [3].

SDF-1α (human) serves as a chemotactic agent for mononuclear cells through its interaction with the CXCR4 receptor, facilitating critical biological processes such as stem cell homing, retention, survival, and proliferation, in addition to cardiomyocyte repair, angiogenesis, and ventricular remodeling post-myocardial infarction. It holds significant utility in cardiovascular disease research [1] [2].

Anti-CXCL12/SDF1a Antibody is a monoclonal antibody specifically targeting Stromal Cell-Derived Factor-1α (SDF-1α/CXCL12). The compound binds to the CXCL12 protein, blocking its interaction with the receptors CXCR4 and CXCR7, thereby inhibiting chemokine-mediated downstream signaling. In experimental research, this antibody is frequently utilized to block directional immune cell migration, suppress tumor cell invasion and metastasis, and attenuate pathological angiogenesis.

SDF-1α (human) TFA is a monocyte chemotactic agent that binds to the CXCR4 receptor. It plays a crucial role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis, and ventricular remodeling in myocardial infarction models. SDF-1α (human) TFA is applicable for cardiovascular disease research.